Imagion Biosystems Appendix 4G and Corporate Governance Statement for the financial year ended 31 December 2018 is available. Download Appendix 4G.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging